HOME >> MEDICINE >> NEWS
UI-led study indicates surgery is the best treatment for severe Bell's palsy paralysis

IOWA CITY, Iowa -- How to best treat patients with Bell's palsy who are at high risk of permanent loss of facial muscle control has remained a controversial subject among physicians for decades. However, results of a 15-year study led by University of Iowa Health Care researchers may help to finally settle the debate.

"We hope these findings will help change the attitudes of a lot of different people," said Bruce Gantz, M.D., UI professor and head of otolaryngology.

Timing and strategy are critical when it comes to the subgroup of patients with Bell's palsy who are at the greatest risks for permanent damage. The study results indicate that identifying this patient population and their subsequent surgical treatment must occur within two weeks of the onset of paralysis.

"If we are going to have any impact, the surgery has to come within the first two weeks," Gantz stressed.

Bell's palsy is partial or complete facial muscle paralysis resulting from a certain dysfunctional cranial nerve that is believed to be damaged by the herpes simplex virus type I. The condition affects about 40,000 Americans per year. Although medication will help most individuals fully or almost fully recover from Bell's palsy paralysis, about 10 to 15 percent of patients will not recover unless additional measures are taken.

The study had three related goals, all attempting to answer the primary questions troubling many clinicians treating patients with Bell's palsy. The researchers wanted to determine how to best identify which patients will be left with poor outcomes, establish whether surgical decompression might improve these patients' chances of recovery, and finally, figure out what, if any, impact time had on treatment.

The study results were based on patient outcomes of individuals with Bell's palsy treated at the UI Hospitals and Clinics, the University of Michigan and the Baylor College of Medicine.

Through their investigation, the UI-led team determin
'"/>

Contact: Jennifer Cronin
jennifer-cronin@uiowa.edu
319-335-9917
University of Iowa
14-Oct-1999


Page: 1 2 3

Related medicine news :

1. UI-led study shows experimental anti-cancer drug also has anti-HIV properties
2. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
3. UMaine study looks at infants and chronic nighttime crying
4. Chronic pain treatments more effective when taken together, new study shows
5. UNC study: Most N.C. family practitioners engage in unrecognized community service
6. New study in Nature demonstrates protection against cell death during heart attack
7. UCSF study offers insight into human circadian rhythms
8. International breast cancer prevention study launches in the United States and Canada
9. UW study shows blacks and Latinos are more satisfied with physicians of the same race
10. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
11. Advertising by academic medical centers may risk eroding public trust, says study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... Dr. Barry ... Avenue Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic ... of the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
(Date:12/5/2016)... ... ... has joined the Retina Group of New York (RGONY) specializing in uveitis and ... and has been providing tertiary medical and surgical retinal care on Long Island for over ... peers. Growing up in a family of doctors, Dr. Shah emulated the role of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Houston ... 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine European ... European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, clinicians, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Swirl: A Wine Tasting Event in New York City, with long-time partners The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Several leading Alzheimer,s disease experts will participate in ... 11 a.m. EST on December 6 in advance of ... Alzheimer,s Disease (CTAD). The program will include discussions on ... targets that address deficient glucose metabolism observed in Alzheimer,s ... another therapy targeting the amyloid hypothesis, now more than ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Florida Institute for the Commercialization of Public Research ... has finalized a funding agreement SegAna, LLC, an ... developed at University of Central Florida. The Florida ... research, and bridges early funding gaps for companies ...
(Date:12/5/2016)... , December 5, 2016 According to a ... modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application ... MarketsandMarkets, the market is projected to reach USD 779.8 Million by ... of 13.5% during the forecast period of 2016 to 2021. ... ...
Breaking Medicine Technology:
Cached News: